Media List

• 

  SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’

  Press Release 2026.08.26

  SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’ Paves the Way to Launch its Second Innovative Drug Directly in the U.S.   -  ....

• 

  SK Biopharmaceuticals In-licenses Its Second Radiopharmaceutical Candidate from WARF

  Press Release 2025.11.27

  SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation   New addition ....

• 

  SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Platform

  Press Release 2025.10.21

  SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform   SK Biopharmaceuticals forms a joint venture, Mentis Care, to dev....

• Notice of Amendments to SK Biopharmaceuticals Co., Ltd. Privacy Policy and Consent Form

  Events 2025.06.17

  Notice of Amendments to SK Biopharmaceuticals Co., Ltd. Privacy Policy and Consent Form Thank you for visiting the SK Biopharmaceuticals website. We would like to inform you th....

• 

  SK Biopharmaceuticals, ProEn Therapeutics Join Hands for Radiopharmaceuticals

  Press Release 2024.12.17

  SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiven....

• 

  SK Biopharmaceuticals, KIRAMS Seal Collaborative Research Agreement

  Press Release 2024.11.19

  SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radio....

• SK Biopharmaceuticals’ Partner Eurofarma Submits Prioritized NDA for Cenobamate in Brazil

  Press Release 2024.10.08

  [Translated ver.]   SK Biopharmaceuticals’ Partner Eurofarma Submits Prioritized NDA for Cenobamate in Brazil   Korea and Brazil, Oct. 8, 2024 – ....

• 

  SK Biopharmaceuticals, Full-Life Technologies Enter Licensing Agreement

  Press Release 2024.07.17

  SK Biopharmaceuticals, Full-Life Technologies Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors SK Biopharmaceuticals, Full-Life Technologies se....

• 

  Mobilizing at 2024 Bio

  Press Release 2024.06.03

    Mobilizing at 2024 Bio SK Biopharmaceuticals has mobilized its U.S. subsidiaries SK Life Science, Inc. and SK Life Science Labs to promote their busines....

• 

  SK Biopharmaceuticals Posts 2024 Q1 Turnaround, Setting the Stage for Annual Profit

  Press Release 2024.05.09

  SK Biopharmaceuticals Posts 2024 Q1 Turnaround, Setting the Stage for Annual Profit   Sales reach KRW 114 billion, operating profit hits KRW 10.3 billion XCOPRI®....